| [1] |
Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation(the Framingham Heart Study) [J]. Am J Cardiol, 1999,83(6):897-902.
|
| [2] |
Coffey S, d'Arcy JL, Loudon MA, et al. The OxVALVE population cohort study (OxVALVE-PCS) -population screening for undiagnosed valvular heart disease in the elderly: study design and objectives[J]. Open Heart, 2014,1(1):e000043.
|
| [3] |
Gössl M, Stanberry L, Benson G, et al. Burden of undiagnosed valvular heart disease in the elderly in the community: heart of new ulm valve study[J]. JACC Cardiovasc Imaging, 2023, 16(8):1118-1120.
|
| [4] |
Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism,and management[J]. J Am Coll Cardiol, 2009, 53(5):401-408.
|
| [5] |
Généreux P, Pibarot P, Redfors B, et al. Staging classification of aortic stenosis based on the extent of cardiac damage[J]. Eur Heart J, 2017, 38(45):3351-3358.DOI: 10.1093/eurheartj/ehx381.
|
| [6] |
Vassileva CM, Shabosky J, Boley T, et al. Tricuspid valve surgery: the past 10 years from the Nationwide Inpatient Sample (NIS) database[J]. J Thorac Cardiovasc Surg, 2012,143(5):1043-1049.
|
| [7] |
Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery[J]. J Am Coll Cardiol, 2017, 70(24):2953-2960.
|
| [8] |
Maisano F, Hahn R, Sorajja P, et al. Transcatheter treatment of the tricuspid valve: current status and perspectives[J]. Eur Heart J, 2024, 45(11):876-894.
|
| [9] |
Hahn RT, Lawlor MK, Davidson CJ, et al. Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial endpoints[J]. J Am Coll Cardiol,2023, 82(17):1711-1735.
|
| [10] |
Davidson LJ, Tang GHL, Ho EC, et al. Council on Cardiovascular surgery and anesthesia; and council on cardiovascular and stroke nursing. the tricuspid valve: a review of pathology, imaging, and current treatment options: a scientific statement from the American Heart Association[J]. Circulation, 2024, 149(22):e1223-e1238.
|
| [11] |
Hahn RT, Weckbach LT, Noack T, et al. Proposal for a standard echocardiographic tricuspid valve nomenclature[J]. JACC Cardiovasc Imaging, 2021, 14(7):1299-1305.
|
| [12] |
Prihadi EA, van der Bijl P, Gursoy E, et al. Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history[J]. Eur Heart J, 2018, 39(39):3574-3581.
|
| [13] |
Mutlak D, Khalil J, Lessick J, et al. Risk factors for the development of functional tricuspid regurgitation and their population-attributable fractions[J]. JACC Cardiovasc Imaging, 2020, 13(8):1643-1651.
|
| [14] |
Wang N, Fulcher J, Abeysuriya N, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis[J]. Eur Heart J, 2019, 40(5):476-484.
|
| [15] |
Offen S, Playford D, Strange G, et al. Adverse prognostic impact of even mild or moderate tricuspid regurgitation:insights from the national echocardiography database of Australia[J]. J Am Soc Echocardiogr, 2022, 35(8):810-817.
|
| [16] |
Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting[J]. JACC Cardiovasc Imaging, 2019,12(3):433-442.
|
| [17] |
Wang TKM, Akyuz K, Mentias A, et al. Contemporary etiologies, outcomes, and novel risk score for isolated tricuspid regurgitation[J]. JACC Cardiovasc Imaging, 2022,15(5):731-744.
|
| [18] |
Dreyfus J, Audureau E, Bohbot Y, et al. TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery[J]. Eur Heart J, 2022,43(7):654-662.
|
| [19] |
Yang L, Chen H, Pan W, et al. Analyses for prevalence and outcome of tricuspid regurgitation in China: an echocardiography study of 134, 874 patients[J].Cardiology, 2019, 142(1):40-46.
|
| [20] |
Xu H, Liu Q, Cao K, et al. Distribution, characteristics, and management of older patients with valvular heart disease in China: China-DVD study[J]. JACC Asia, 2022, 2(3):354-365.
|
| [21] |
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2021, 143(5):e35-e71.
|
| [22] |
Adamo M, Chioncel O, Pagnesi M, et al. Epidemiology,pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC[J]. Eur J Heart Fail, 2024, 26(1):18-33.
|
| [23] |
Patlolla SH, Schaff HV, Nishimura RA, et al. Incidence and burden of tricuspid regurgitation in patients with atrial fibrillation[J]. J Am Coll Cardiol, 2022, 80(24):2289-2298.
|
| [24] |
Cho MS, Cha MJ, Nam GB, et al. Incidence and predictors of severe tricuspid regurgitation in atrial fibrillation patients without structural heart disease[J]. Am J Cardiol,2023, 203:288-294.
|
| [25] |
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632.
|
| [26] |
Chen Q, Bowdish ME, Malas J, et al. Isolated tricuspid operations: the society of thoracic surgeons adult cardiac surgery database analysis[J]. Ann Thorac Surg, 2023,115(5):1162-1170.
|
| [27] |
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation[J]. N Engl J Med, 2023, 388(20):1833-1842.
|
| [28] |
Kodali SK, Hahn RT, Davidson CJ, et al. 1-year outcomes of transcatheter tricuspid valve repair[J]. J Am Coll Cardiol,2023, 81(18):1766-1776.
|
| [29] |
Gray WA, Abramson SV, Lim S, et al. 1-year outcomes of cardioband tricuspid valve reconstruction system early feasibility study[J]. JACC Cardiovasc Interv, 2022,15(19):1921-1932.
|
| [30] |
Zhang X, Jin Q, Pan W, et al. First-in-human study of the K-Clip ™ transcatheter annular repair system for severe functional tricuspid regurgitation[J]. Int J Cardiol,2023,390:131174.
|
| [31] |
Kodali SK. TRISCEND Ⅱ : a randomized trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation[EB/OL]. (2023-10-27)[2024-09-10] https://www.tctmd.com/slide/triscend-ii-randomized-trial-transcatheter-tricuspid-valve-replacement-patients-severe.
|
| [32] |
Zhang Y, Lu F, Li W, et al. A first-in-human study of transjugular transcatheter tricuspid valve replacement with the LuX-Valve Plus system[J]. EuroIntervention,2023, 18(13):e1088-e1089.
|
| [33] |
Ge J. One-month outcomes of the multicenter TRAVEL Ⅱ(transvascular tricuspid valve replacement with the LuX-Valve Plus System)study[EB/OL]. (2023-10-26)[2024-09-10] https://www.tctmd.com/slide/one-month-outcomes-multicenter-travel-ii-transvasculartricuspid-valve-replacement-lux-valve.
|
| [34] |
Blasco-Turrión S, Briedis K, Estévez-Loureiro R, et al.Bicaval TricValve implantation in patients with severe symptomatic tricuspid regurgitation: 1-year follow-up outcomes[J]. JACC Cardiovasc Interv, 2024, 17(1):60-72.
|
| [35] |
McElhinney DB, Cabalka AK, Aboulhosn JA, et al.Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international, multicenter registry study[J].Circulation, 2016, 133(16):1582-1593.
|
| [36] |
Bouleti C, Himbert D, Brochet E, et al. Transfemoral tricuspid valve-in-ring implantation using the edwards Sapien XT valve: one-year follow-up[J]. Circ Cardiovasc Interv, 2015, 8(3) :e002225.
|
| [37] |
Condado J, Leonardi R, Babaliaros V. Percutaneous tricuspid valve-in-ring replacement for the treatment of recurrent severe tricuspid regurgitation[J]. Catheter Cardiovasc Interv, 2015, 86(7):1294-1298.
|
| [38] |
Besler C, Orban M, Rommel KP, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair[J]. JACC Cardiovasc Interv, 2018, 11(12):1119-1128.
|
| [39] |
Utsunomiya H, Itabashi Y, Mihara H,et al. Usefulness of 3D echocardiographic parameters of tricuspid valve morphology to predict residual tricuspid regurgitation after tricuspid annuloplasty[J]. Eur Heart J Cardiovasc Imaging, 2017, 18(7):809-817.
|
| [40] |
Fukuda S, Song JM, Gillinov AM, et al. Tricuspid valve tethering predicts residual tricuspid regurgitation after tricuspid annuloplasty[J]. Circulation, 2005, 111(8):975-979.
|
| [41] |
Praz F, Muraru D, Kreidel F, et al. Transcatheter treatment for tricuspid valve disease[J]. EuroIntervention, 2021,17(10):791-808.
|
| [42] |
Dreyfus J, Galloo X, Taramasso M, et al. TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation[J]. Eur Heart J, 2024, 45(8):586-597.
|
| [43] |
Lu F, Xiong T, Chen M. Evaluation of systemic impact of tricuspid regurgitation: an appeal for the notion of tricuspid regurgitation syndrome[J]. Chin Med J (Engl),2023, 136(2):138-140.
|
| [44] |
Brener MI, Lurz P, Hausleiter J, et al. Right ventricular-pulmonary arterial coupling and afterload reserve in patients undergoing transcatheter tricuspid valve repair[J]. J Am Coll Cardiol, 2022, 79(5):448-461.
|
| [45] |
Fortuni F, Butcher SC, Dietz MF, et al. Right ventricular-pulmonary arterial coupling in secondary tricuspid regurgitation[J]. Am J Cardiol, 2021, 148:138-145.
|
| [46] |
Sugiura A, Tanaka T, Kavsur R, et al. Leaflet configuration and residual tricuspid regurgitation after transcatheter edge-to-edge tricuspid repair[J]. JACC Cardiovasc Interv,2021, 14(20):2260-2270.
|
| [47] |
Park JB, Kim HK, Jung JH, et al. Prognostic value of cardiac MR imaging for preoperative assessment of patients with severe functional tricuspid regurgitation[J]. Radiology,2016, 280(3):723-734.
|
| [48] |
Grapsa J, Praz F, Sorajja P, et al. Tricuspid regurgitation:from imaging to clinical trials to resolving the unmet need for treatment[J]. JACC Cardiovasc Imaging, 2024, 17(1):79-95.
|
| [49] |
Abraham WT, Psotka MA, Fiuzat M, et al. Standardized definitions for evaluation of heart failure therapies:scientific expert panel from the heart failure collaboratory and academic research consortium[J]. JACC Heart Fail, 2020, 8(12):961-972.
|
| [50] |
Ferreira JP, Duarte K, Graves TL, et al. Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials[J]. J Am Coll Cardiol, 2016, 68(24):2690-2707.
|
| [51] |
Addetia K, Miyoshi T, Amuthan V, et al. Normal values of three-dimensional right ventricular size and function measurements: results of the world alliance societies of echocardiography study[J]. J Am Soc Echocardiogr, 2023,36(8):858-866.e1.
|
| [52] |
Hahn RT, Kodali S, Fam N, et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation[J]. JACC Cardiovasc Interv, 2020, 13(21):2482-2493.
|
| [53] |
Buğan B, Çekirdekçi Eİ, Onar LÇ, et al. Transcatheter tricuspid valve replacement for tricuspid regurgitation: a systematic review and Meta-analysis[J]. Anatol J Cardiol,2022, 26(7):505-519.
|
| [54] |
Kodali S, Hahn RT, George I, et al. Transfemoral tricuspid valve replacement in patients with tricuspid regurgitation: TRISCEND study 30-day results[J]. JACC Cardiovasc Interv, 2022, 15(5):471-480.
|